Patents by Inventor David J. Glass
David J. Glass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11834508Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.Type: GrantFiled: March 16, 2021Date of Patent: December 5, 2023Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
-
Patent number: 11800829Abstract: A work machine includes a work machine actuator, a position sensor configured to sense a geographic position of the work machine on a worksite and a control system configured to receive an indication of a thematic map of the worksite that maps variable values to different geographic locations on the worksite, generate a set of clusters based on the variable values and a geospatial control zone constraint, identify, based on the set of clusters, a plurality of control zones that are correlated to the worksite and have associated setting values, and generate control signals to control the work machine actuator based on the geographic position of the work machine relative to the plurality of control zones and the setting values associated with the control zones.Type: GrantFiled: February 3, 2020Date of Patent: October 31, 2023Assignee: Deere & CompanyInventors: Jeffrey S. Sidon, Sam R. Helmich, Scott W. Anderson, David J. Glass
-
Patent number: 11337356Abstract: A crop orientation system includes a controller having a processor and memory coupled to the processor and storing instructions. The processor executes the stored instructions to: determine first heading values for a first vehicle at intervals during a first crop planting event over a first field; generate a first set of histogram values representing the first heading values for the first vehicle during at least a portion of the first crop planting event over the first field; and generate display signals to render a first histogram display based on the first set of histogram values for a first user associated with the first vehicle.Type: GrantFiled: March 12, 2020Date of Patent: May 24, 2022Assignee: DEERE & COMPANYInventors: Sam R. Helmich, David J. Glass
-
Publication number: 20210309749Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.Type: ApplicationFiled: March 16, 2021Publication date: October 7, 2021Inventors: Anthony ROSENZWEIG, Jason D. ROH, David J. GLASS
-
Publication number: 20210282309Abstract: A crop orientation system includes a controller having a processor and memory coupled to the processor and storing instructions. The processor executes the stored instructions to: determine first heading values for a first vehicle at intervals during a first crop planting event over a first field; generate a first set of histogram values representing the first heading values for the first vehicle during at least a portion of the first crop planting event over the first field; and generate display signals to render a first histogram display based on the first set of histogram values for a first user associated with the first vehicle.Type: ApplicationFiled: March 12, 2020Publication date: September 16, 2021Inventors: Sam R. Helmich, David J. Glass
-
Publication number: 20210176916Abstract: A work machine includes a work machine actuator, a position sensor configured to sense a geographic position of the work machine on a worksite and a control system configured to receive an indication of a thematic map of the worksite that maps variable values to different geographic locations on the worksite, generate a set of clusters based on the variable values and a geospatial control zone constraint, identify, based on the set of clusters, a plurality of control zones that are correlated to the worksite and have associated setting values, and generate control signals to control the work machine actuator based on the geographic position of the work machine relative to the plurality of control zones and the setting values associated with the control zones.Type: ApplicationFiled: February 3, 2020Publication date: June 17, 2021Inventors: Jeffrey S. SIDON, Sam R. HELMICH, Scott W. ANDERSON, David J. Glass
-
Patent number: 10982000Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.Type: GrantFiled: March 20, 2018Date of Patent: April 20, 2021Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
-
Publication number: 20200031940Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.Type: ApplicationFiled: March 20, 2018Publication date: January 30, 2020Inventors: Anthony ROSENZWEIG, Jason D. ROH, David J. GLASS
-
Patent number: 8445434Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.Type: GrantFiled: March 9, 2012Date of Patent: May 21, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Publication number: 20120195896Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.Type: ApplicationFiled: March 9, 2012Publication date: August 2, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: David J. GLASS, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Patent number: 8158581Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.Type: GrantFiled: September 30, 2010Date of Patent: April 17, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Publication number: 20110020342Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.Type: ApplicationFiled: September 30, 2010Publication date: January 27, 2011Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: DAVID J. GLASS, GEORGE D. YANCOPOULOS, THOMAS J. DALY, NICHOLAS J. PAPADOPOULOS
-
Patent number: 7837999Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.Type: GrantFiled: June 6, 2008Date of Patent: November 23, 2010Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Patent number: 7781404Abstract: Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction.Type: GrantFiled: February 26, 2009Date of Patent: August 24, 2010Assignee: Regeneron Pharmaceuticals, Inc.Inventor: David J. Glass
-
Patent number: 7632503Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.Type: GrantFiled: February 14, 2008Date of Patent: December 15, 2009Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Trevor Stitt, Esther Latres, David J. Glass
-
Publication number: 20090175864Abstract: Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction.Type: ApplicationFiled: February 26, 2009Publication date: July 9, 2009Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: David J. Glass
-
Patent number: 7521211Abstract: A chimeric protein comprising an IGF1 and an IGF2 component and optionally a fusion component (F) and/or a signal sequence, exhibiting improved activity relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound.Type: GrantFiled: March 31, 2006Date of Patent: April 21, 2009Assignee: Regeneron Pharmaceuticals, IncInventor: David J. Glass
-
Publication number: 20090069235Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.Type: ApplicationFiled: June 6, 2008Publication date: March 12, 2009Inventors: David J. GLASS, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
-
Publication number: 20080199479Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.Type: ApplicationFiled: February 14, 2008Publication date: August 21, 2008Inventors: Trevor Stitt, Esther Latres, David J. Glass
-
Patent number: 7396918Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.Type: GrantFiled: January 6, 2006Date of Patent: July 8, 2008Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos